Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Participants With Type 2 Diabetes, Moderate Impairment of Kidney Function, and Inadequate Blood Sugar Control

ClinicalTrials.gov ID: NCT03242252

Public ClinicalTrials.gov record NCT03242252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled, 3-arm, Parallel-group 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Mellitus and Moderate Renal Impairment Who Have Inadequate Glycemic Control

Study identification

NCT ID
NCT03242252
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Lexicon Pharmaceuticals
Industry
Enrollment
787 participants

Conditions and interventions

Interventions

  • Placebo Drug
  • Sotagliflozin Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 15, 2017
Primary completion
Mar 24, 2019
Completion
Oct 24, 2019
Last update posted
Jun 24, 2021

2017 – 2019

United States locations

U.S. sites
51
U.S. states
20
U.S. cities
45
Facility City State ZIP Site status
Investigational Site Number 8404018 Birmingham Alabama 35205
Investigational Site Number 8404045 Guntersville Alabama 35976-2206
Investigational Site Number 8404004 Phoenix Arizona 85018-2701
Investigational Site Number 8404022 Phoenix Arizona 85050-7500
Investigational Site Number 8404007 Little Rock Arkansas 72205
Investigational Site Number 8404023 Chula Vista California 91910
Investigational Site Number 8404044 Gold River California 95670
Investigational Site Number 8404011 Los Angeles California 90057
Investigational Site Number 8404003 Norco California 92860
Investigational Site Number 8404025 Northridge California 91324
Investigational Site Number 8404038 San Dimas California 91713
Investigational Site Number 8404019 Clearwater Florida 33761
Investigational Site Number 8404001 DeLand Florida 32720-0834
Investigational Site Number 8404006 Ocoee Florida 34761-4547
Investigational Site Number 8404064 Orlando Florida 32806
Investigational Site Number 8404043 Ormond Beach Florida 32174-8187
Investigational Site Number 8404013 Palmetto Bay Florida 33157-5503
Investigational Site Number 8404016 Savannah Georgia 31406
Investigational Site Number 8404040 Wauconda Illinois 60084-2452
Investigational Site Number 8404036 Lake Charles Louisiana 70601
Investigational Site Number 8404020 New Orleans Louisiana 70119-6302
Investigational Site Number 8404014 Norfolk Nebraska 68701
Investigational Site Number 8404032 Papillion Nebraska 68046-3136
Investigational Site Number 8404048 Hackensack New Jersey 07601-1963
Investigational Site Number 8404074 New York New York 00000
Investigational Site Number 8404009 The Bronx New York 10455
Investigational Site Number 8404051 Wilmington North Carolina 28401-6638
Investigational Site Number 8404028 Winston-Salem North Carolina 27103-3914
Investigational Site Number 8404029 Winston-Salem North Carolina 27103-4027
Investigational Site Number 8404026 Dayton Ohio 45419-4336
Investigational Site Number 8404052 Lansdale Pennsylvania 19446-1002
Investigational Site Number 8404031 Anderson South Carolina 29621
Investigational Site Number 8404021 Mt. Pleasant South Carolina 29464
Investigational Site Number 8404056 Chattanooga Tennessee 37404
Investigational Site Number 8404015 Austin Texas 78726-4061
Investigational Site Number 8404050 Austin Texas 78731
Investigational Site Number 8404060 Austin Texas 78749
Investigational Site Number 8404005 Beaumont Texas 77702
Investigational Site Number 8404035 Dallas Texas 75208
Investigational Site Number 8404039 Houston Texas 77058
Investigational Site Number 8404055 Houston Texas 77099
Investigational Site Number 8404012 Hurst Texas 76054
Investigational Site Number 8404033 Lampasas Texas 76550-1820
Investigational Site Number 8404053 McAllen Texas 78504
Investigational Site Number 8404057 Round Rock Texas 78681
Investigational Site Number 8404059 San Antonio Texas 78212
Investigational Site Number 8404010 San Antonio Texas 78249-2782
Investigational Site Number 8404008 Layton Utah 84041-1200
Investigational Site Number 8404042 Renton Washington 98057
Investigational Site Number 8404041 Seattle Washington 98105
Investigational Site Number 8404047 Kenosha Wisconsin 53144

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 119 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03242252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 24, 2021 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03242252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →